MPLT
MapLight Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$13.77
+4.79%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 585.0K | 578.0K | 701.0K | 556.0K | 574.0K |
| Gross Profit | (585.0K) | (578.0K) | (701.0K) | (556.0K) | (574.0K) |
| Operating Expenses | |||||
| R&D Expense | 198.7M | 137.8M | 67.8M | 49.1M | 26.6M |
| SG&A Expense | 43.8M | 30.7M | 14.4M | 7.6M | 4.1M |
| General & Admin Expense | 4.4M | — | 14.4M | 7.6M | 4.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 242.5M | 168.5M | 82.2M | 56.7M | 30.7M |
| Cost and Expenses | 242.9M | 169.1M | 82.9M | 57.3M | 31.2M |
| Operating Income (EBIT) | (242.9M) | (169.1M) | (82.9M) | (57.3M) | (31.2M) |
| Non-Operating | |||||
| Interest Income | 8.8M | 5.5M | 4.5M | 1.1M | 429.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 8.8M | 5.5M | 4.5M | 1.1M | 429.0K |
| Other Non-Op Income/Expense | 13.1M | 7.9M | 5.4M | 1.6M | 1.2M |
| Non-Operating Income (excl Interest) | (9.7M) | (7.9M) | (5.4M) | (1.6M) | (1.2M) |
| EBT (Pre-Tax Income) | (229.8M) | (161.2M) | (77.6M) | (55.7M) | (30.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (229.8M) | (161.2M) | (77.6M) | (55.7M) | (30.0M) |
| Earnings from Cont. Ops | (229.8M) | (161.2M) | (77.6M) | (55.7M) | (30.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (229.8M) | (161.2M) | (77.6M) | (55.7M) | (30.0M) |
| Per Share | |||||
| Basic EPS | ($5.18) | ($3.66) | ($1.87) | ($1.34) | ($0.72) |
| Diluted EPS | ($5.18) | ($3.66) | ($1.87) | ($1.34) | ($0.72) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 45.4M | 44.0M | 41.4M | 41.4M | 41.4M |
| Diluted Shares Outstanding | 45.4M | 44.0M | 41.4M | 41.4M | 41.4M |
| Profitability Metrics | |||||
| EBITDA | (232.6M) | (160.6M) | (76.9M) | (55.2M) | (29.4M) |
| D&A | 585.0K | 578.0K | 701.0K | 556.0K | 574.0K |
| EBIT | (233.2M) | (161.2M) | (77.6M) | (55.7M) | (30.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026